Details for Patent: 8,557,993
✉ Email this page to a colleague
Which drugs does patent 8,557,993 protect, and when does it expire?
Patent 8,557,993 protects LIVALO and is included in one NDA.
Protection for LIVALO has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has thirty-six patent family members in nine countries.
Summary for Patent: 8,557,993
| Title: | Crystalline forms of pitavastatin calcium |
| Abstract: | The present invention is directed to new crystalline forms of Pitavastatin hemicalcium salt, referred to hereinafter as polymorphic Forms A, B, C, D, E and F, as well as the amorphous form. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and the amorphous form and pharmaceutical compositions comprising these crystalline forms or the amorphous forms. |
| Inventor(s): | Van der Schaaf; Paul Adriaan (Hagenthal-le-Haut, FR), Blatter; Fritz (Reinach, CH), Szelagiewicz; Martin (Muenchenstein, CH), Schoening; Kai-Uwe (Oberwil, CH) |
| Assignee: | Nissan Chemical Industries Ltd. (Tokyo, JP) |
| Application Number: | 13/664,498 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,557,993 |
|
Patent Claim Types: see list of patent claims | Compound; Process; Composition; |
Drugs Protected by US Patent 8,557,993
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kowa Co | LIVALO | pitavastatin calcium | TABLET;ORAL | 022363-001 | Aug 3, 2009 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Kowa Co | LIVALO | pitavastatin calcium | TABLET;ORAL | 022363-002 | Aug 3, 2009 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Kowa Co | LIVALO | pitavastatin calcium | TABLET;ORAL | 022363-003 | Aug 3, 2009 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,557,993
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| 03405080 | Feb 12, 2003 | |
International Family Members for US Patent 8,557,993
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2004212160 | ⤷ Try a Trial | |||
| Canada | 2513837 | ⤷ Try a Trial | |||
| Canada | 2785954 | ⤷ Try a Trial | |||
| China | 100374422 | ⤷ Try a Trial | |||
| China | 101219992 | ⤷ Try a Trial | |||
| China | 102285916 | ⤷ Try a Trial | |||
| China | 1747934 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
